lipaglyn.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | Lipaglyn | Hypertriglyceridemia | Atherogenic Diabetic Dyslipidemia | Diabetic |
| Description | LIPAGLYN - The novel drug for treating Diabetic Lipaglyn is the first Lipaglyn, Hypertriglyceridemia, Atherogenic Diabetic Dyslipidemia, Diabetic Dyslipidemia to be approved and it is the first New Chemical Entity (NCE) discovered and developed indigenously by an Indian Pharma |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 192.169.201.23 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
lipaglyn.com Valuation
|
US$255,395
Last updated: 2023-04-27 09:26:06
lipaglyn.com has Semrush global rank of 41,442,991. lipaglyn.com has an estimated worth of US$ 255,395, based on its estimated Ads revenue. lipaglyn.com receives approximately 29,469 unique visitors each day. Its web server is located in United States, with IP address 192.169.201.23. According to SiteAdvisor, lipaglyn.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$255,395 |
| Daily Ads Revenue | US$236 |
| Monthly Ads Revenue | US$7,073 |
| Yearly Ads Revenue | US$84,870 |
| Daily Unique Visitors | 1,965 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| lipaglyn.com. | A | 10800 | IP: 192.169.201.23 |
| lipaglyn.com. | NS | 3600 | NS Record: ns49.domaincontrol.com. |
| lipaglyn.com. | NS | 3600 | NS Record: ns50.domaincontrol.com. |
| lipaglyn.com. | MX | 3600 | MX Record: 0 mail.lipaglyn.com. |
| lipaglyn.com. | TXT | 3600 | TXT Record: v=spf1 a mx ptr include:secureserver.net ~all |
HtmlToTextCheckTime:2023-04-27 09:26:06
| Diabetic Dyslipidemia Rated 4.2 /5 based on 1426 reviews Home About About Lipaglyn About Zydus About ZRC Doctors Patients Health Blog FAQs News Room Updates Events Contact us Novel drug to treat Diabetic Dyslipidemia – a global, unmet healthcare need --> Novel NCE from an Indian research pipeline to move from the lab to the market A Novel Therapy to treat Diabetic Dyslipidemia Zydus becomes the 1st Indian Pharma Company to launch an NCE It’s first-of-its kind novel action works as a lipid regulator and also provides glycemic benefits This marks the beginning of India’s contribution to the world of drug discovery LIPAGLYN - The novel drug for treating Diabetic Dyslipidemia combines lipid and glucose lowering effects in one single molecule. Read More... --> Diabetic Dyslipidemia Diabetic Dyslipidemia is a condition where a person is diabetic and has elevated levels of the total cholesterol About Lipaglyn Lipaglyn™ is the first NCE discovered and developed indigenously by an Indian |
HTTP Headers
HTTP/1.1 200 OK Date: Wed, 20 Oct 2021 14:20:20 GMT Server: Apache Last-Modified: Wed, 13 Jan 2021 09:39:19 GMT Accept-Ranges: bytes Content-Length: 21874 Connection: close Content-Type: text/html |
lipaglyn.com Whois Information
Domain Name: LIPAGLYN.COM Registry Domain ID: 1798346277_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.PublicDomainRegistry.com Registrar URL: http://www.publicdomainregistry.com Updated Date: 2021-03-23T11:14:05Z Creation Date: 2013-05-02T11:52:35Z Registry Expiry Date: 2022-05-02T11:52:35Z Registrar: PDR Ltd. d/b/a PublicDomainRegistry.com Registrar IANA ID: 303 Registrar Abuse Contact Email: abuse-contact@publicdomainregistry.com Registrar Abuse Contact Phone: +1.2013775952 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS49.DOMAINCONTROL.COM Name Server: NS50.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2021-09-09T03:46:25Z <<< |